Registry Search

KYTRIL

Comprehensive clinical and safety monograph for KYTRIL (KYTRIL).

KYXATA

Comprehensive clinical and safety monograph for KYXATA (KYXATA).

KYZATREX

Comprehensive clinical and safety monograph for KYZATREX (KYZATREX).

L-GLUTAMINE

Comprehensive clinical and safety monograph for L-GLUTAMINE (L-GLUTAMINE).

Labetalol

First-line oral antihypertensive for chronic hypertension in pregnancy and acute management of severe-range blood pressures (≥160/110 mmHg) alongside IV formulations. Extensive safety data; no consistent link to structural defects. Neonatal monitoring recommended when used at delivery.

LABETALOL HYDROCHLORIDE

Other drugs that lower heart rate or blood pressure can have additive effects Can cause liver injury and bronchospasm in susceptible patients.

LABETALOL HYDROCHLORIDE IN DEXTROSE

Other drugs that lower heart rate or blood pressure can have additive effects Can cause liver injury and bronchospasm in susceptible patients.

LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

No significant drug interactions Can cause hypernatremia and fluid overload.

LABID

Comprehensive clinical and safety monograph for LABID (LABID).

LAC-HYDRIN

Comprehensive clinical and safety monograph for LAC-HYDRIN (LAC-HYDRIN).

LACOSAMIDE

No significant drug interactions May cause dizziness and PR interval prolongation.

LACRISERT

Comprehensive clinical and safety monograph for LACRISERT (LACRISERT).

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

Comprehensive clinical and safety monograph for LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER (LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER).

LACTATED RINGER'S IN PLASTIC CONTAINER

Comprehensive clinical and safety monograph for LACTATED RINGER'S IN PLASTIC CONTAINER (LACTATED RINGER'S IN PLASTIC CONTAINER).

LACTULOSE

Comprehensive clinical and safety monograph for LACTULOSE (LACTULOSE).

LAMICTAL

Comprehensive clinical and safety monograph for LAMICTAL (LAMICTAL).

LAMICTAL CD

Comprehensive clinical and safety monograph for LAMICTAL CD (LAMICTAL CD).

LAMICTAL ODT

Comprehensive clinical and safety monograph for LAMICTAL ODT (LAMICTAL ODT).

LAMICTAL XR

Comprehensive clinical and safety monograph for LAMICTAL XR (LAMICTAL XR).

LAMISIL

Comprehensive clinical and safety monograph for LAMISIL (LAMISIL).

LAMISIL AT

Comprehensive clinical and safety monograph for LAMISIL AT (LAMISIL AT).

LAMIVUDINE

Trimethoprim/sulfamethoxazole increases lamivudine exposure Severe acute exacerbations of hepatitis B have been reported upon discontinuation.

LAMIVUDINE AND STAVUDINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

LAMIVUDINE AND ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

LAMIVUDINE, NEVIRAPINE, AND STAVUDINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

LAMIVUDINE; STAVUDINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

LAMIVUDINE; STAVUDINE; NEVIRAPINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

LAMIVUDINE; ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

LAMIVUDINE; ZIDOVUDINE; ABACAVIR

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

Lamivudine/Zidovudine 150 mg/300 mg Tablets Co-packaged with Nevirapine 200 mg Tablets

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

Lamotrigine

The preferred antiepileptic drug for women of reproductive age and the most commonly used AED in pregnancy. Associated with the lowest major congenital malformation (MCM) rate of the major AEDs in the largest pregnancy registries (NAAED: approximately 2.0–2.4% vs. 2–3% background rate for low doses). Dose-dependent teratogenicity seen only at high doses (>300 mg/day) in some registries, but risk at therapeutic doses is low. Critical caveat: pregnancy significantly increases lamotrigine clearance (by up to 2–3×), requiring dose adjustment to prevent breakthrough seizures.

LAMPIT

Comprehensive clinical and safety monograph for LAMPIT (LAMPIT).

LAMPRENE

Comprehensive clinical and safety monograph for LAMPRENE (LAMPRENE).

LAMZEDE

Comprehensive clinical and safety monograph for LAMZEDE (LAMZEDE).

LANABIOTIC

Comprehensive clinical and safety monograph for LANABIOTIC (LANABIOTIC).

LANIAZID

Comprehensive clinical and safety monograph for LANIAZID (LANIAZID).

LANOPHYLLIN

Comprehensive clinical and safety monograph for LANOPHYLLIN (LANOPHYLLIN).

LANORINAL

Comprehensive clinical and safety monograph for LANORINAL (LANORINAL).

LANOXICAPS

Comprehensive clinical and safety monograph for LANOXICAPS (LANOXICAPS).

LANOXIN

Comprehensive clinical and safety monograph for LANOXIN (LANOXIN).

LANOXIN PEDIATRIC

Comprehensive clinical and safety monograph for LANOXIN PEDIATRIC (LANOXIN PEDIATRIC).